Department of Respiratory Medicine, Sir Charles Gairdner Hospital, Perth; Centre for Asthma, Allergy, and Respiratory Research, University of Western Australia, Perth; School of Medicine and Pharmacology, University of Western Australia, Perth.
School of Medicine and Pharmacology, University of Western Australia, Perth; Department of Respiratory Medicine, Royal Perth Hospital, Perth.
Chest. 2012 Aug;142(2):394-400. doi: 10.1378/chest.11-2657.
Patients with malignant pleural effusion (MPE) have limited prognoses. They require long-lasting symptom relief with minimal hospitalization. Indwelling pleural catheters (IPCs) and talc pleurodesis are approved treatments for MPE. Establishing the implications of IPC and talc pleurodesis on subsequent hospital stay will influence patient choice of treatment. Therefore, our objective was to compare patients with MPE treated with IPC vs pleurodesis in terms of hospital bed days (from procedure to death or end of follow-up) and safety.
In this prospective, 12-month, multicenter study, patients with MPE were treated with IPC or talc pleurodesis, based on patient choice. Key end points were hospital bed days from procedure to death (total and effusion-related). Complications, including infection and protein depletion, were monitored longitudinally.
One hundred sixty patients with MPE were recruited, and 65 required definitive fluid control; 34 chose IPCs and 31 pleurodesis. Total hospital bed days (from any causes) were significantly fewer in patients with IPCs (median, 6.5 days; interquartile range [IQR] = 3.75-13.0 vs pleurodesis, mean, 18.0; IQR, 8.0-26.0; P = .002). Effusion-related hospital bed days were significantly fewer with IPCs (median, 3.0 days; IQR, 1.8-8.3 vs pleurodesis, median, 10.0 days; IQR, 6.0-18.0; P < .001). Patients with IPCs spent significantly fewer of their remaining days of life in hospital (8.0% vs 11.2%, P < .001, χ(2) = 28.25). Fewer patients with IPCs required further pleural procedures (13.5% vs 32.3% in pleurodesis group). There was no difference in rates of pleural infection (P = .68) and protein (P = .65) or albumin loss (P = .22). More patients treated with IPC reported immediate (within 7 days) improvements in quality of life and dyspnea.
Patients treated with IPCs required significantly fewer days in hospital and fewer additional pleural procedures than those who received pleurodesis. Safety profiles and symptom control were comparable.
恶性胸腔积液(MPE)患者预后有限。他们需要长期缓解症状,同时尽量减少住院时间。留置胸腔导管(IPC)和滑石粉胸膜固定术是 MPE 的批准治疗方法。确定 IPC 和滑石粉胸膜固定术对随后住院时间的影响将影响患者的治疗选择。因此,我们的目的是比较 MPE 患者接受 IPC 与胸膜固定术治疗在住院天数(从手术到死亡或随访结束)和安全性方面的差异。
在这项前瞻性、12 个月、多中心研究中,根据患者的选择,对 MPE 患者进行 IPC 或滑石粉胸膜固定术治疗。主要终点是从手术到死亡(总住院天数和胸腔积液相关住院天数)的住院天数。并发症,包括感染和蛋白消耗,进行了纵向监测。
共招募了 160 例 MPE 患者,其中 65 例需要明确的液体控制;34 例选择 IPC,31 例选择胸膜固定术。IPC 组患者的总住院天数(任何原因)明显少于胸膜固定术组(中位数 6.5 天,四分位距 [IQR] = 3.75-13.0 vs 胸膜固定术组 18.0 天,IQR = 8.0-26.0;P =.002)。IPC 组胸腔积液相关住院天数明显少于胸膜固定术组(中位数 3.0 天,IQR = 1.8-8.3 vs 胸膜固定术组 10.0 天,IQR = 6.0-18.0;P <.001)。IPC 组患者在生命剩余天数中住院的天数明显减少(8.0% vs 11.2%,P <.001,χ(2) = 28.25)。IPC 组需要进一步胸膜治疗的患者比例明显较低(13.5% vs 胸膜固定术组 32.3%)。胸膜感染率(P =.68)、蛋白丢失率(P =.65)或白蛋白丢失率(P =.22)无差异。更多接受 IPC 治疗的患者报告在 7 天内立即改善生活质量和呼吸困难。
与接受胸膜固定术的患者相比,接受 IPC 治疗的患者需要住院的天数明显减少,需要进行的额外胸膜治疗次数也明显减少。安全性和症状控制相当。